DK3529262T3 - Fremgangsmåder til fremme af t-cellerespons - Google Patents

Fremgangsmåder til fremme af t-cellerespons Download PDF

Info

Publication number: DK3529262T3
Authority: DK; Denmark
Prior art keywords: promoting; procedures; cell response; cell; response
Prior art date: 2016-10-21

Application number

DK17797066.2T

Other languages

English (en)

Inventor

Elise Chiffoleau

Géraldine TEPPAZ

Nicolas Poirier

Bernard Vanhove

Vanessa Gauttier

Original Assignee

Inst Nat Sante Rech Med

Univ Nantes

Ose Immunotherapeutics

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-21

Filing date

2017-10-20

Publication date

2021-09-20

2017-10-20 Application filed by Inst Nat Sante Rech Med, Univ Nantes, Ose Immunotherapeutics filed Critical Inst Nat Sante Rech Med

2021-09-20 Application granted granted Critical

2021-09-20 Publication of DK3529262T3 publication Critical patent/DK3529262T3/da

Links

0 C*(C)**(NCCCC*)I Chemical compound C*(C)**(NCCCC*)I 0.000 description 3

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1732—Lectins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Marine Sciences & Fisheries (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

DK17797066.2T 2016-10-21 2017-10-20 Fremgangsmåder til fremme af t-cellerespons DK3529262T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP16306381		2016-10-21
EP17305988		2017-07-24
PCT/EP2017/076911 WO2018073440A1 (en)	2016-10-21	2017-10-20	Methods for promoting t cells response

Publications (1)

Publication Number	Publication Date
DK3529262T3 true DK3529262T3 (da)	2021-09-20

Family

ID=60293924

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17797066.2T DK3529262T3 (da)	2016-10-21	2017-10-20	Fremgangsmåder til fremme af t-cellerespons

Country Status (20)

Country	Link
US (2)	US11365257B2 (da)
EP (2)	EP3950709B1 (da)
JP (2)	JP7032396B6 (da)
KR (1)	KR102646708B1 (da)
CN (1)	CN110291102A (da)
AU (1)	AU2017345286B2 (da)
CA (1)	CA3039348C (da)
CY (1)	CY1124584T1 (da)
DK (1)	DK3529262T3 (da)
ES (1)	ES2883678T3 (da)
HR (1)	HRP20211544T1 (da)
HU (1)	HUE056016T2 (da)
IL (1)	IL266111B (da)
LT (1)	LT3529262T (da)
MA (1)	MA46570B1 (da)
MD (1)	MD3529262T2 (da)
PL (1)	PL3529262T3 (da)
RS (1)	RS62463B1 (da)
SI (1)	SI3529262T1 (da)
WO (1)	WO2018073440A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MD3529262T2 (ro) *	2016-10-21	2022-01-31	Inst Nat Sante Rech Med	Metode pentru promovarea răspunsului celulelor T
AU2018229351B2 (en)	2017-02-28	2024-01-04	Vor Biopharma, Inc.	Compositions and methods for inhibition of lineage specific proteins
CA3110837A1 (en) *	2018-08-28	2020-03-05	Vor Biopharma Inc.	Genetically engineered hematopoietic stem cells and uses thereof
JP2023504733A (ja)	2019-12-05	2023-02-06	オーエスイー・イミュノセラピューティクス	抗ｃｌｅｃ－１ａ抗体及びその抗原結合性断片
EP4352097A1 (en)	2021-06-08	2024-04-17	Ose Immunotherapeutics	Humanized anti-clec-1a antibodies and antigen-binding fragments thereof and mimetics thereof
WO2023083890A1 (en) *	2021-11-09	2023-05-19	Ose Immunotherapeutics	Identification of clec-1 ligand and uses thereof
WO2024028347A1 (en)	2022-08-01	2024-02-08	Ose Immunotherapeutics	Heterodimeric fc-clec-1 fusion molecule and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5229275A (en)	1990-04-26	1993-07-20	Akzo N.V.	In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
ES2162823T5 (es)	1992-08-21	2010-08-09	Vrije Universiteit Brussel	Inmunoglobulinas desprovistas de cadenas ligeras.
US5618829A (en)	1993-01-28	1997-04-08	Mitsubishi Chemical Corporation	Tyrosine kinase inhibitors and benzoylacrylamide derivatives
ATE361759T1 (de)	1993-07-15	2007-06-15	Cancer Res Campaign Tech	Verbindungen die zur herstellung von protein- tyrosin-kinase-inhibitor-prodrogen verwendet werden können
EP0690452A3 (en)	1994-06-28	1999-01-07	Advanced Micro Devices, Inc.	Electrically erasable memory and method of erasure
US5804396A (en)	1994-10-12	1998-09-08	Sugen, Inc.	Assay for agents active in proliferative disorders
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5639757A (en)	1995-05-23	1997-06-17	Pfizer Inc.	4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
JP3370340B2 (ja)	1996-04-12	2003-01-27	ワーナー―ランバート・コンパニー	チロシンキナーゼの不可逆的阻害剤
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
US6100254A (en)	1997-10-10	2000-08-08	Board Of Regents, The University Of Texas System	Inhibitors of protein tyrosine kinases
US6740665B1 (en)	1999-02-10	2004-05-25	Ramachandran Murali	Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en)	1999-03-11	2001-06-12	Merck & Co., Inc.	Tyrosine kinase inhibitors
ATE253915T1 (de)	1999-06-30	2003-11-15	Merck & Co Inc	Src-kinase hemmende verbindungen
EP1206260A4 (en)	1999-06-30	2002-10-30	Merck & Co Inc	SRC-KINASE INHIBITING COMPOUNDS
JP2003503354A (ja)	1999-06-30	2003-01-28	メルクエンドカムパニーインコーポレーテッド	Ｓｒｃキナーゼ阻害剤化合物
CZ2002861A3 (cs)	1999-09-10	2002-06-12	Merck & Co., Inc.	Inhibitory tyrosinkinázy
EP1226119B1 (en)	1999-10-19	2005-03-16	MERCK & CO. INC.	Tyrosine kinase inhibitors
US6794393B1 (en)	1999-10-19	2004-09-21	Merck & Co., Inc.	Tyrosine kinase inhibitors
ES2234698T3 (es)	1999-10-19	2005-07-01	MERCK & CO., INC.	Inhibidores de tirosina quinasa.
DE60033062T2 (de) *	1999-11-15	2007-08-23	Miltenyi Biotec Gmbh	Antikörper spezifisch für dendritische zellen, zusammensetzungen und verfahren, die diese antikörper verwenden, das durch die antikörper detektierte antigen und die dadurch erhaltenen zellen
US6420382B2 (en)	2000-02-25	2002-07-16	Merck & Co., Inc.	Tyrosine kinase inhibitors
US6313138B1 (en)	2000-02-25	2001-11-06	Merck & Co., Inc.	Tyrosine kinase inhibitors
AU2002346053B2 (en)	2001-06-22	2008-03-13	Merck & Co., Inc.	Tyrosine kinase inhibitors
US6958340B2 (en)	2001-08-01	2005-10-25	Merck & Co., Inc.	Tyrosine kinase inhibitors
WO2003020276A1 (en)	2001-08-30	2003-03-13	Merck & Co., Inc.	Tyrosine kinase inhibitors
US8246959B1 (en)	2003-08-01	2012-08-21	University Of Washington	Dendritic cell-associated lectin-like molecules, compositions and methods of use
WO2007109571A2 (en)	2006-03-17	2007-09-27	Prometheus Laboratories, Inc.	Methods of predicting and monitoring tyrosine kinase inhibitor therapy
JP2010519313A (ja) *	2007-02-23	2010-06-03	ベイラーリサーチインスティテュート	Ｃｌｅｃ−６を介したヒト抗原提示細胞の活性化
US20130058957A1 (en) *	2010-02-23	2013-03-07	The University Of Tokyo	Dendritic cell immunoreceptor agonist
BR112017000939A2 (pt) *	2014-07-21	2017-11-14	Novartis Ag	tratamento de câncer usando um receptor antigênico quimérico de cll-1
MD3529262T2 (ro) *	2016-10-21	2022-01-31	Inst Nat Sante Rech Med	Metode pentru promovarea răspunsului celulelor T

2017
- 2017-10-20 MD MDE20190953T patent/MD3529262T2/ro unknown
- 2017-10-20 LT LTEPPCT/EP2017/076911T patent/LT3529262T/lt unknown
- 2017-10-20 SI SI201730876T patent/SI3529262T1/sl unknown
- 2017-10-20 KR KR1020197014209A patent/KR102646708B1/ko active IP Right Grant
- 2017-10-20 PL PL17797066T patent/PL3529262T3/pl unknown
- 2017-10-20 EP EP21178847.6A patent/EP3950709B1/en active Active
- 2017-10-20 DK DK17797066.2T patent/DK3529262T3/da active
- 2017-10-20 RS RS20211221A patent/RS62463B1/sr unknown
- 2017-10-20 CN CN201780065072.6A patent/CN110291102A/zh active Pending
- 2017-10-20 MA MA46570A patent/MA46570B1/fr unknown
- 2017-10-20 HU HUE17797066A patent/HUE056016T2/hu unknown
- 2017-10-20 AU AU2017345286A patent/AU2017345286B2/en active Active
- 2017-10-20 WO PCT/EP2017/076911 patent/WO2018073440A1/en active Application Filing
- 2017-10-20 HR HRP20211544TT patent/HRP20211544T1/hr unknown
- 2017-10-20 IL IL266111A patent/IL266111B/en unknown
- 2017-10-20 ES ES17797066T patent/ES2883678T3/es active Active
- 2017-10-20 US US16/343,757 patent/US11365257B2/en active Active
- 2017-10-20 CA CA3039348A patent/CA3039348C/en active Active
- 2017-10-20 JP JP2019521034A patent/JP7032396B6/ja active Active
- 2017-10-20 EP EP17797066.2A patent/EP3529262B1/en active Active
2021
- 2021-09-24 CY CY20211100839T patent/CY1124584T1/el unknown
2022
- 2022-02-22 JP JP2022025697A patent/JP7404418B6/ja active Active
- 2022-05-10 US US17/740,849 patent/US20220281983A1/en active Pending

Also Published As

Publication number	Publication date
HUE056016T2 (hu)	2022-01-28
EP3529262A1 (en)	2019-08-28
KR20190068605A (ko)	2019-06-18
HRP20211544T1 (hr)	2022-01-07
JP2020503252A (ja)	2020-01-30
MA46570B1 (fr)	2021-10-29
JP7032396B2 (ja)	2022-03-08
JP7404418B2 (ja)	2023-12-25
US20190309075A1 (en)	2019-10-10
EP3950709A1 (en)	2022-02-09
LT3529262T (lt)	2021-11-10
US20220281983A1 (en)	2022-09-08
ES2883678T3 (es)	2021-12-09
CN110291102A (zh)	2019-09-27
CY1124584T1 (el)	2022-07-22
CA3039348A1 (en)	2018-04-26
CA3039348C (en)	2023-09-05
JP2022065159A (ja)	2022-04-26
JP7404418B6 (ja)	2024-01-26
IL266111B (en)	2022-09-01
IL266111A (en)	2019-06-30
EP3950709B1 (en)	2024-02-14
EP3529262B1 (en)	2021-07-21
MA46570A (fr)	2021-03-31
RS62463B1 (sr)	2021-11-30
KR102646708B1 (ko)	2024-03-12
AU2017345286A1 (en)	2019-04-18
MD3529262T2 (ro)	2022-01-31
US11365257B2 (en)	2022-06-21
JP7032396B6 (ja)	2022-03-22
SI3529262T1 (sl)	2021-12-31
WO2018073440A1 (en)	2018-04-26
PL3529262T3 (pl)	2021-12-27
AU2017345286B2 (en)	2023-08-03

Publication	Publication Date	Title
DK3463248T3 (da)	2022-10-31	Anordnnger til anvendelse af lægemiddelanordninger
DK3346961T3 (da)	2020-08-17	Anordning til stomi
DK3192902T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3294700T3 (da)	2020-04-14	Fremgangsmåde til fremstilling af limonen-4-ol
DK3072835T3 (da)	2019-07-29	Fremgangsmåde til fremføring
DK3096741T3 (da)	2020-09-28	Fremgangsmåde til fremstillingen af hybridosomer
DK3300500T3 (da)	2020-05-18	Triazolagonister af apj-receptoren
DK3174858T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af pyrazoler
DK3325443T3 (da)	2022-07-18	Fremgangsmåde til fremstilling af pridopidin
DK3126373T3 (da)	2020-05-04	Fremgangsmåde til fremstilling af amg 416
DK3303618T3 (da)	2019-12-16	Fremgangsmåder til prognose af prostatacancer
DK3507408T3 (da)	2021-04-06	Fremgangsmåde til fremstilling af nonwoven
DK3529262T3 (da)	2021-09-20	Fremgangsmåder til fremme af t-cellerespons
DK3529233T3 (da)	2020-10-12	Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3222717T3 (da)	2020-06-29	Fremgangsmåde til at amplificere cirkulært dna
DK3233813T3 (da)	2022-03-07	Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3280408T3 (da)	2020-02-03	Fremgangsmåde til fremstilling af dicycloplatin
DK3519094T3 (da)	2020-08-31	System til forberedelse af en prøve
DK3274143T3 (da)	2019-11-25	Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3166855T3 (da)	2021-10-18	Fremgangsmåde for tilvejebringelse af foldelinjer
DK3164716T3 (da)	2020-04-06	Fremgangsmåde til diagnosticering af neurodegenerative sygdomme
DE112016005541A5 (de)	2018-08-09	Arylierungsverfahren
DK3302788T3 (da)	2021-06-14	Fremgangsmåde til fremstilling af en sorbent
DK3507282T3 (da)	2021-02-01	Fremgangsmåde til fremstilling af indolcarboxamidforbindelser
DK3467005T3 (da)	2020-09-28	Fremgangsmåde til opnåelse af bionedbrydeligt polyesteretheramid